- Home
- DNLI vs COGT Comparison
DNLI vs COGT Comparison
Compare DNLI & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- COGT
- Stock Information
- Founded
- DNLI 2013
- COGT 2014
- Country
- DNLI United States
- COGT United States
- Employees
- DNLI N/A
- COGT N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- DNLI Health Care
- COGT Health Care
- Exchange
- DNLI Nasdaq
- COGT Nasdaq
- Market Cap
- DNLI 2.2B
- COGT 2.3B
- IPO Year
- DNLI 2017
- COGT 2018
- Fundamental
- Price
- DNLI $14.85
- COGT $14.35
- Analyst Decision
- DNLI Strong Buy
- COGT Strong Buy
- Analyst Count
- DNLI 13
- COGT 12
- Target Price
- DNLI $32.64
- COGT $22.00
- AVG Volume (30 Days)
- DNLI 1.5M
- COGT 2.4M
- Earning Date
- DNLI 11-03-2025
- COGT 10-31-2025
- Dividend Yield
- DNLI N/A
- COGT N/A
- EPS Growth
- DNLI N/A
- COGT N/A
- EPS
- DNLI N/A
- COGT N/A
- Revenue
- DNLI N/A
- COGT N/A
- Revenue This Year
- DNLI N/A
- COGT N/A
- Revenue Next Year
- DNLI $94,232.03
- COGT N/A
- P/E Ratio
- DNLI N/A
- COGT N/A
- Revenue Growth
- DNLI N/A
- COGT N/A
- 52 Week Low
- DNLI $10.57
- COGT $3.72
- 52 Week High
- DNLI $33.33
- COGT $17.15
- Technical
- Relative Strength Index (RSI)
- DNLI 42.38
- COGT 42.90
- Support Level
- DNLI $15.53
- COGT $14.20
- Resistance Level
- DNLI $17.02
- COGT $16.76
- Average True Range (ATR)
- DNLI 0.75
- COGT 0.90
- MACD
- DNLI -0.23
- COGT -0.27
- Stochastic Oscillator
- DNLI 9.18
- COGT 16.67
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.